The policy described below has been published. HHS, rather than the FDA, posted its "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances" on October 28, and the Federal Register published the notice on October 30 under the same tracking number, RIN 0910-ZD94. It covers the six peptides named below, it's a draft open for public comment, and on Baker Hostetler's and the FDA Law Blog's readings it comes with conditions, starting with a prescription for an individual patient. Our write-up, HHS has published its peptide compounding policy, has what it covers and what it doesn't. The rest of this page is our October 27 reporting, with only its tense and headings adjusted so it reads as a record.
What happened
As of October 27, no pharmacy route had opened, because the policy that would open it hadn't been published. On October 14, the FDA sent a document titled "Interim Access Policy for Compounding Using Certain Peptides" to the White House Office of Management and Budget, which reviews agency policies before they go out. The government's own review tracker, reginfo.gov, listed it as a notice still pending review on October 27. The text hadn't been made public, so nobody outside government knew which peptides it named, what conditions it set or when it would start.
The plan surfaced a week earlier. The Washington Post reported on October 7 that the administration was preparing a stopgap to let some previously restricted peptides be sold while new rules are written. After the submission, the Associated Press reported on October 15 that the policy is meant to let pharmacies temporarily compound some of the most popular peptides, BPC-157 among them.
The likeliest candidates are the six the FDA's Pharmacy Compounding Advisory Committee recommended in July: BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax. BPC-157, KPV and TB-500 each passed by the same 8 to 6 split, and we covered the vote in our write-up. Until the policy was published, its actual list was a guess, including ours. It turned out to be exactly these six.
Three different things that all get called "legal"
Most of the confusion in this story comes from three separate things being treated as one.
The law is the federal rule on compounding and its official list of ingredients a compounding pharmacy may use, called the 503A Bulks List. Adding a peptide to that list takes formal rulemaking, which the AP notes can take years. The advisory vote is what happened in July. It was advice to the FDA and bound nobody. The enforcement policy is what was at the White House on October 27, the government telling pharmacies it won't act against them for compounding certain substances. That approach is called enforcement discretion, and it leaves the law exactly where it was.
What the lawyers expected it to do
Holland & Knight's Sarah Starling Crossan and Shalyn Watkins, writing on October 16, call enforcement discretion "the most likely approach," possibly by moving the peptides into what the FDA calls Category 1. Under the FDA's interim rules for compounding ingredients, Category 1 covers substances still under evaluation that the agency doesn't intend to act against if pharmacies meet set conditions. Category 2 is where the FDA puts substances it has flagged for significant safety risks, and the AP reports BPC-157 and more than a dozen other injectable peptides were put on that too-risky list.
The same firm is clear about the limits. In its reading, the policy wouldn't approve any product or change the underlying statute, wouldn't bind state pharmacy and medical boards, wouldn't cover the larger outsourcing facilities known as 503B, and wouldn't extend to research-use or supplement sales. It also "could be narrowed or withdrawn at any time without a formal public comment process." The American Med Spa Association put the same point more bluntly: enforcement discretion is not approval, and these peptides would remain unapproved drugs.
The case against, in one paragraph
On October 13, KFF Health News, in a piece co-published with the Washington Post, reported on people who say BPC-157 and other peptides left them with migraines, facial numbness and fatigue, and on FDA scientists who told the July panel the evidence of benefit was thin and the risks included liver damage and allergic reactions. Supporters argue the decision belongs with a prescriber and a pharmacist rather than with the agency. Both arguments were set to return the day the policy text appeared.
What it meant for you on October 27
If you were waiting on a pharmacy route, nothing had opened yet. If the policy were issued the way Holland & Knight expected, it would mean a prescription from a licensed prescriber, a state-licensed 503A pharmacy willing to make it, and whatever your state's pharmacy board allows. It would also be temporary by design. A pharmacy or clinic advertising compounded BPC-157 "under the new FDA policy" on October 27 was selling ahead of a document nobody had seen.
If you bought research-use, this policy, on the lawyers' reading, wasn't about you, and the FDA was still policing how those products were marketed, as the August warning letters showed. The variables you controlled were the same ones as the month before, the vendor and the price. Our price comparison tool and vendor directory are where to check both, and a listing that suddenly calls a compound FDA-approved or newly legal is a reason to look harder at the seller.
What we said to watch, and what happened
We said the first signal would be the reginfo.gov listing changing from pending to concluded, then the published text. The text arrived on October 28, posted by HHS, and the Federal Register notice followed on October 30, so our write-up of the published policy is the current one. How state pharmacy boards respond is still the thing to watch. A second advisory committee meeting is also due before the end of February 2027 with five more peptides, which we previewed here.
Sources
- 1. "Interim Access Policy for Compounding Using Certain Peptides," RIN 0910-ZD94, received October 14, 2026, status pending review. Office of Information and Regulatory Affairs, reginfo.gov, checked October 27, 2026.
- 2. Crossan, Sarah Starling, and Shalyn Watkins. "Peptides at a Crossroads: What Wellness Providers Need to Know About HHS and FDA Actions." Holland & Knight, October 16, 2026.
- 3. "Trump administration advances plan for peptide drugs favored by RFK Jr." Associated Press, via STAT, October 15, 2026.
- 4. "The Trump administration is paving way for temporary sale of some unapproved peptides." The Washington Post, via Anchorage Daily News, October 7, 2026.
- 5. "FDA Sends Peptide 'Interim Access Policy' to White House for Review." American Med Spa Association, October 16, 2026.
- 6. Maxmen, Amy. "People Say These Peptides Hurt Them. Their Stories Are Muffled in MAHA's Push for Medical Freedom." KFF Health News, October 13, 2026.
- 7. "Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act." U.S. Food and Drug Administration, accessed October 27, 2026.
- 8. "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances," Docket HHS-OASH-2026-0496, FR Doc. 2026-22192. Department of Health and Human Services, Federal Register, filed October 28, published October 30, 2026. Added in the October 30 update.
- 9. "HHS Issues Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances." Baker Hostetler, October 2026. Added in the October 30 update.
- 10. "The PEPTIDE-L Wave Reaches HHS: Enforcement Discretion ... Not the Finish Line." FDA Law Blog, October 2026. Added in the October 30 update.